Mats Lindskog, member

Born in 1974. Board member since 2023.

MSc in Chemical Engineering and PhD in Biotechnology in antibody-based proteomics, Royal Institute of Technology, Stockholm.

Conducted research in identification of new cancer genes at the Stockholm Bioinformatics Centre. Extensive experience in business development, drug sales and antibody technology through various senior positions at pharmaceutical companies in business unit management, business excellence and commercial operations. Member of Swedish, Nordic and Nordic-Baltic management teams at the pharmaceutical companies Unimedic Pharma, Allergan, Shire, AstraZeneca and Amgen.

Other ongoing assignments: since 2021 Chief Business Officer (CBO) Oblique Therapeutics AB (publ), which is active in the cancer field.

Shareholding WntResearch: 0